Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Baxter
AstraZeneca
Moodys
Express Scripts

Last Updated: May 25, 2022

Investigational Drug Information for Lucerastat


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for Lucerastat?

Lucerastat is an investigational drug.

There have been 7 clinical trials for Lucerastat. The most recent clinical trial was a Phase 3 trial, which was initiated on December 18th 2018.

The most common disease conditions in clinical trials are Fabry Disease and [disabled in preview]. The leading clinical trial sponsors are Idorsia Pharmaceuticals Ltd., Actelion, and [disabled in preview].

There are fifty-eight US patents protecting this investigational drug and three hundred and sixty-six international patents.

Recent Clinical Trials for Lucerastat
TitleSponsorPhase
A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart FunctionIdorsia Pharmaceuticals Ltd.Phase 1
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry DiseaseIdorsia Pharmaceuticals Ltd.Phase 3
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry DiseaseIdorsia Pharmaceuticals Ltd.Phase 3

See all Lucerastat clinical trials

Clinical Trial Summary for Lucerastat

Top disease conditions for Lucerastat
Top clinical trial sponsors for Lucerastat

See all Lucerastat clinical trials

US Patents for Lucerastat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lucerastat See Plans and Pricing Cell lines for virus production and methods of use University of Georgia Research Foundation, Inc. (Athens, GA) The United States of America, as represented by the Secretary, Dept. of Health and Human Services (Washington, DC) Thermo Fisher Scientific, Inc. (Waltham, MA) See Plans and Pricing
Lucerastat See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Lucerastat See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
Lucerastat See Plans and Pricing Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN) See Plans and Pricing
Lucerastat See Plans and Pricing Therapeutic agent for fibrosis and inhibitor of nuclear translocation of phosphorylated smad NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (Chiba-Shi, JP) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Lucerastat

Drugname Country Document Number Estimated Expiration Related US Patent
Lucerastat Australia AU2014215025 2033-02-05 See Plans and Pricing
Lucerastat Canada CA2899928 2033-02-05 See Plans and Pricing
Lucerastat China CN105121645 2033-02-05 See Plans and Pricing
Lucerastat China CN108588027 2033-02-05 See Plans and Pricing
Lucerastat European Patent Office EP2954055 2033-02-05 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Baxter
AstraZeneca
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.